Wegovy and Ozempic prices drop 50% — but there’s a catch for most Americans

Drug giant slashes list prices up to 50%

Novo Nordisk announced on Feb. 24 that it will drop the monthly list price of Wegovy, Ozempic, and Rybelsus to $675 across all doses.

The new price kicks in Jan. 1, 2027. These are wholesale prices, meaning the base cost before any rebates or insurance discounts.

For Wegovy, that’s about a 50% cut from its current list price of roughly $1,349. Ozempic and Rybelsus see about a 35% cut from around $1,028.

Some patients will save big at the pharmacy

The lower list price targets insured patients whose out-of-pocket costs are tied directly to what a drug lists for.

That includes people on high-deductible health plans or coinsurance setups, where patients pay a percentage of the listed cost. Under those plans, a lower list price means a smaller bill at the pharmacy counter.

Jamey Millar, Novo Nordisk’s executive vice president of U.S. operations, said the change aims to “remove cost barriers for more patients.”

Cash-pay and Medicare patients won’t see changes

If you already buy these drugs out of pocket through NovoCare Pharmacy or retail savings programs, this cut doesn’t change your price.

Those patients already pay between $149 and $499 per month depending on the drug and dose. Medicare beneficiaries also have separate, lower prices set through government deals.

And patients with standard insurance plans that already cover these drugs at a flat copay may not notice any difference either.

Medicare sets its own price through government deals

Medicare patients won’t pay the $675 list price. Under the Inflation Reduction Act, Medicare negotiated a price of about $274 per month for Ozempic and about $386 for higher Wegovy doses, starting Jan. 1, 2027.

On top of that, Novo Nordisk signed a Most Favored Nation deal with the Trump administration in November 2025, setting Medicare and Medicaid prices at $245 per month.

The government said the MFN price will replace the earlier negotiated price. Under that deal, Medicare patients pay no more than $50 per month.

Eli Lilly keeps the pressure on

Novo Nordisk isn’t cutting prices in a vacuum.

Eli Lilly, which makes rival drugs Zepbound and Mounjaro, has been slashing prices too, offering Zepbound through its LillyDirect platform for $299 to $449 per month for cash-paying patients.

Both companies signed MFN pricing deals with the Trump administration in November 2025. Eli Lilly reported a 45% jump in 2025 revenue, while Novo Nordisk projected a sales decline of 5% to 13% for 2026.

Novo Nordisk says the list price cut is unrelated to its MFN deal.

Government and competition both drive prices down

The U.S. government has pushed for lower drug prices through both the Inflation Reduction Act and Trump’s Most Favored Nation executive order.

Both Novo Nordisk and Eli Lilly got three-year tariff exemptions as part of their MFN agreements. Cash-pay and direct-to-consumer channels now make up a growing share of new prescriptions.

The compounding industry, which sold cheaper copycat versions during a drug shortage, has also put pressure on both companies.

Novo Nordisk says more than 100 million Americans live with obesity and over 35 million have type 2 diabetes.

“List price” doesnt mean what you actually pay

A drug’s list price is the base cost set by the manufacturer before any rebates, discounts, or insurance deals. Most insured patients don’t pay the full list price because their insurance company negotiates lower rates.

But for patients on high-deductible plans, their share often gets calculated as a percentage of that list price.

So a 50% cut could cut their out-of-pocket cost roughly in half.

Still, Citi analyst Geoffrey Meacham noted the cut may only help a small portion of new prescriptions, since cash-pay channels now hold the bulk of new patient starts.

These drugs treat more than weight loss

Wegovy, Ozempic, and Rybelsus all contain semaglutide, a GLP-1 receptor agonist.

Wegovy is approved for adults with obesity or overweight with related health problems, and for children 12 and older with obesity. Ozempic is approved for type 2 diabetes and chronic kidney disease in adults with type 2 diabetes.

Both Wegovy and Ozempic can also reduce the risk of major heart events like heart attack and stroke in certain patients. No other GLP-1 drug has this same range of approved uses, according to Novo Nordisk.

Wegovy now comes as a pill too

Novo Nordisk launched an oral version of Wegovy in early 2026, and it’s included in the list price cut at $675 per month starting in 2027.

Cash-paying patients can get the pill’s starting dose for $149 per month right now. The oral version gives patients an alternative to the weekly injection.

The pill launch has been a bright spot for Novo Nordisk even as the company faces pricing pressure across the board.

GLP-1 demand hits an all-time high

Demand for GLP-1 drugs has never been higher in the United States.

Researchers found that U.S. obesity rates dipped for the first time in over a decade, and suggested weight-loss drugs may have played a role.

An estimated 20 to 25 million patients now take GLP-1 drugs from both Novo Nordisk and Eli Lilly. New oral versions from both companies could expand the market even further.

The pricing landscape has shifted fast over the past year, with government deals, competition, and direct-to-consumer channels all pushing costs down.

The $675 price doesn’t start until 2027

The new list price takes effect Jan. 1, 2027. Until then, current list prices stay in place for insured patients.

Cash-paying patients can already get lower prices through NovoCare Pharmacy and other discount channels.

Medicare patients will see their own lower prices start on the same date under government-negotiated deals.

Patients should check with their insurance plan or pharmacist to find out how this change affects their specific costs.

Multiple price tracks make things confusing

There are now several different prices for the same drugs.

Cash-pay patients pay $149 to $499 per month through NovoCare or retail savings programs. Insured patients on high-deductible plans will see prices based on the new $675 list price starting in 2027.

Medicare patients will pay no more than $50 per month under the MFN deal. Patients can talk to their pharmacist to find out which price applies to them.

This article was created with AI assistance and human editing.

Read more from this brand:

• TrumpRx Asks You to Choose: Insurance or Cheaper Drugs. You Can’t Have Both.
• Your Medicare bill just got a 10-year forecast and it’s not pretty
• Pharma Companies Raise Prices on 350+ Meds Despite White House Deal